Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Comprehensive Sickle Cell Disease Program of Greenville Health System
900 W. Faris Road, 2nd FloorGreenville, South Carolina, United States
Phone Web
Over the last 30 years, children with sickle cell disease (SCD) have seen drastic improvements in their survival and quality of life through a standardized approach to treatment, disease modification, and preventive care. Adults with SCD, on the other hand, have often found it difficult to access these types of services and end up experiencing a higher amount of disease-related complications. In order to meet the needs of all individuals with SCD in our community, regardless of age, we have created the Comprehensive Sickle Cell Disease Program of Greenville Health System.
Services provided:
• Patient-centered, compassionate care for children and adults with SCD
• Dedicated care team (social work, psychology, nursing, medical providers) providing outpatient and inpatient services
• Outpatient infusion program for delivery of pain medications, fluids, antibiotics, and blood transfusions
• Management of disease modifying medications, such as Hydroxyurea and Endari
• In-office stroke risk screening with Transcranial Doppler (TCD) Ultrasound
• Chronic RBC transfusion program with apheresis capabilities on-site
• Standardized transition program designed to educate support and adolescents as they move into the adult model of care
• Social work and case management services
• School Intervention Program (SIP)
• Access to local and national research protocols
+myBinderRelated Content
-
Acute Vaso-Occlusive Episode in Sickle Cell AnemiaAcute Vaso-Occlusive Episode in Sickle C...
-
Risk Factors for 30-Day Readmission in Adults with Sickle Cell DiseaseBACKGROUND: Readmission to the hospital...
-
Spearheading change on World Sickle Cell DayThis year on World Sickle Cell Day, a ne...
-
Sickle Cell Disease Association of America Michigan Chapter, Inc.The vision of Sickle Cell Disease Associ...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Sickle Cell Disease Program at Arkansas Children’sArkansas Children's is the only hospital...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
